Completed PHASE3 INTERVENTIONAL 2-arm NCT00546637

Fesoterodine add-on Male Overactive Bladder Study

A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Fesoterodine As An Add-On Therapy In Men With Persistent Overactive Bladder Symptoms Under Monotherapy Of Alpha Blocker For Lower Urinary Tract Symptoms.

Sponsor: Pfizer

Conditions Overactive Bladder Syndrome

Interventions Fesoterodine Placebo

Updated 7 times since 2017 Last updated: Feb 15, 2011 Started: Nov 30, 2007 Primary completion: Feb 28, 2009 Completion: Feb 28, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Overactive Bladder Syndrome, this trial is completed. The trial is conducted by Pfizer and has accumulated 7 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Amphoe Mueang, Thailand , Antwerp, Belgium , Aurora, United States , Austin, United States , Bacolod City, Philippines , Bala-Cynwyd, United States , Baltimore, United States , Banská Bystrica, Slovakia , Barrie, Canada and 113 more locations